Search

Displaying results 2301 - 2310 of 9667 in total
  1. Drug

    Levallorphan

    go.drugbank.com/drugs/DB00504
    Approved

    It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants … (From Martindale, The Extra Pharmacopoeia, 30th ed, p683)

  2. Drug

    Coagulation Factor IX (Recombinant)

    go.drugbank.com/drugs/DB00100
    Approved

    It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor IX. … medium that is then processed and purified for use as a pharmaceutical agent.

  3. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. … [A189207] Ubrogepant was approved by Health Canada on November 10, 2022.

  4. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    erythematosus, but so far only anifrolumab has been approved. … [A237054] Anifrolumab has also been investigated for the treatment of Scleroderma.[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929]

  5. Drug

    Tazarotene

    go.drugbank.com/drugs/DB00799
    Approved

    It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage). … Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids.

  6. Drug

    Ceftobiprole medocaril

    go.drugbank.com/drugs/DB14733
    Approved

    [L50467] It received its first approval in Canada in October 2017 for use in certain patients with bacterial pneumonia,[L50472] and was subsequently approved in the United States with additional indications

  7. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [A237610] Further investigations revealed that dynorphins, endogenous agonists of KORs, work to inhibit the itching sensation at the spinal cord level, and scratching could be elicited in mouse models … [L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665]

  8. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.

  9. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. … It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.

  10. Drug

    Follitropin

    go.drugbank.com/drugs/DB00066
    ApprovedInvestigational

    The nomenclature “beta” differentiates it from another recombinant human FSH product that was marketed earlier as follitropin alpha. … The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24.